Background: Sialylation, a key terminal glycosylation modification, plays a pivotal role in tumor progression and immune evasion. The sialyltransferase ST3GAL4 is implicated in individual cancers, but its pan-cancer landscape and systemic associations remain undefined. Methods: We performed an integrated multi-omics analysis using transcriptomic, proteomic, genomic, DNA methylation, and tumor microenvironment datasets from TCGA, CPTAC, GTEx, and other public resources. Immune associations were evaluated via TIMER2.0 and TISIDB. Experimental validation included immunofluorescence staining for ST3GAL4 protein in human tumor specimens. Results: ST3GAL4 exhibited pervasive, lineage-specific dysregulation across cancers. Elevated expression correlated with adverse prognosis, genomic instability, and specific RNA modification patterns. Tumor microenvironment analyses revealed significant associations: ST3GAL4 expression positively correlated with cancer-associated fibroblast and endothelial cell infiltration but was inversely associated with cytotoxic T-cell abundance. Functional enrichment implicated ST3GAL4 within glycosphingolipid metabolism and glycan biosynthetic pathways. In experimental models, its expression demonstrated context-dependent modulation following cytokine stimulation and immunotherapy. Immunofluorescence confirmed tumor-specific protein expression and its spatial co-occurrence with stromal and immune cell markers. Conclusions: This multi-omics study delineates a comprehensive pan-cancer atlas of ST3GAL4, establishing its association with aggressive tumor behavior, an immunosuppressive microenvironment, and core glycosylation pathways. These findings position ST3GAL4 as a potential cross-tumor node linking sialylation to immune evasion, providing a rationale for future mechanistic and therapeutic exploration.
Background: Calcium/calmodulin-dependent protein kinase II alpha (CAMK2A) is a neuron-enriched kinase that plays essential roles in synaptic signaling and neuronal differentiation. However, its clinical significance and biological relevance in glioma remain incompletely understood. This study aimed to systematically characterize CAMK2A across human cancers and investigate its prognostic significance and association with neuronal differentiation programs in glioma. Methods: An integrated multi-omics analysis was performed using pan-cancer transcriptomic, proteomic, genomic, DNA methylation, bulk RNA-sequencing, and single-cell RNA-sequencing datasets from TCGA, CPTAC, GTEx, CGGA, and other public resources. CAMK2A expression patterns, clinical associations, prognostic value, molecular characteristics, pathway activities, and cellular localization were systematically evaluated. Multiplex immunofluorescence staining of human glioma specimens was further performed to validate the protein-level expression patterns of CaMKII and the neuronal marker MAP2. Results:CAMK2A exhibited lineage-specific dysregulation across human cancers and was progressively downregulated during glioma progression. Higher CAMK2A expression was consistently associated with prolonged overall survival across multiple independent glioma cohorts and remained an independent favorable prognostic factor after adjustment for established clinicopathological and molecular variables. Functional enrichment analyses linked CAMK2A to neuronal differentiation, synaptic organization, calcium signaling, and neurotransmission-related pathways. Gliomas with high CAMK2A expression exhibited lower scores for several malignancy-associated pathways and enrichment of neuronal transcriptional signatures; these tissue-level associations do not distinguish tumor-intrinsic programs from normal neuronal admixture. Single-cell transcriptomic analyses further revealed preferential enrichment of CAMK2A in neuronal populations. Consistently, multiplex immunofluorescence demonstrated a coordinated reduction in CaMKII and MAP2 protein expression with glioma progression. Conclusions:CAMK2A represents a neuron-associated biomarker linked to preserved neuronal differentiation programs and favorable clinical outcomes in glioma. These findings support its potential value as a prognostic biomarker and provide further insight into the relationship between neuronal differentiation programs and glioma progression.